Anti-Factor VIIa polyclonal antibody

Raman spectra of (NH4)(3)TiF7 within spectral range 10-3,400cm(-1) at temperatures 8-370K are recorded, which revealed 2 phase transitions at temperatures T-1=355K and T-2=283K. First principles calculations of lattice dynamics and assignment of the observed lines to specific vibrational types are performed. The first phase transition is classified as an order-disorder one. Manifestation of 97cm(-1) vibration (mixed translational [NH4+F7]) evidences the creation of the hydrogen bond between ammonium group and free fluorine atom, indicating to reconstructive type of phase transition an T-2=283K. The emergence of a large number of vibrational lines in Raman spectra at low temperatures proves symmetry lowering of NH4 tetrahedra with the simultaneous ordering of TiF6 octahedra.

Gastroesophageal reflux disease (GERD) is an esophageal injury occurred when the stomach contents reflux abnormally into the esophagus. GERD complications include esophageal adenocarcinoma. Mosapride (MOS) is a safe prokinetic agent potentially used to treat GERD. Yet, its low solubility and bioavailability due to extensive first-pass metabolism limits its applications. This study aimed to formulate MOS nanostructured lipid carriers (MOS-NLCs) via the intranasal route to improve its bioavailability. Melt-emulsification low temperature-solidification technique using 2(3) full factorial design was adopted to formulate MOS-NLCs. Eight formulae were prepared and assessed in terms of entrapment efficiency (%EE), particle size, and in vitro release. Glycerol addition significantly reduced the particle sizes and improved %EE and %drug released. Surface modification using chitosan was applied. The optimized MOS surface-modified nanostructured lipid carriers (MOS-SMNLCs-F7)(stearic acid, 4% glycerol, 0.5% LuterolF127, 0.5% chitosan) showed low particle size 413.8nm +/- 11.46nm and high %EE 90.19%+/- 0.06% and a threefold increase in permeation of MOS with respect to the drug suspension. MOS-SMNLCs (F7) was also evaluated for its bioavailability compared with drug suspension and commercial product. Statistical analysis revealed a significant increase in gastric emptying rate to be 21.54 +/- 1.88 contractions/min compared with10.02 +/- 0.62 contractions/min and 8.9 +/- 0.72 contractions/min for drug suspension and oral marketed product respectively. Pharmacokinetic studies showed 2.44-fold rise in bioavailability as compared to MOS suspension and 4.54-fold as compared to the oral marketed product. In vitro/in vivo studies proven to level A correlation between in vitro permeation through sheep nasal mucosa and in vivo absorption. Therefore, MOS-SMNLCs could be considered a step forward towards enhancing the clinical efficacy of Mosapride.